CTLA4 and urothelial carcinoma: Several clinical trials to determine the response of urothelial carcinoma to immune checkpoint inhibitors are ongoing and have yielded promising results20,21; moreover, ICIs targeting PD-1 and CTLA-4 have been shown to significantly improve the prognosis of locally advanced and advanced BLCA and are well tolerated22–24.